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Abstract 
 The human genome project has allowed for the rapid identification of a large 
number of protein families based on similarities in their genetic sequences. The acyl-
glycerol phosphate acyltransferase (AGPAT) family of enzymes have been largely 
identified through sequence homology, with eleven isoforms identified in both mice and 
humans. Interestingly, very little work has been done on the characterization of AGPAT 
isoform 4. In the present study, I report the functional characterization of AGPAT4 as a 
lysophosphatidic acid acyltransferase. Although AGPAT4 is present in most tissues, I 
have found that it is abundant in multiple brain regions including olfactory bulbs, 
hippocampus, cerebellum, cortex, and brain stem, and is detectable in both primary 
neurons and glial cells. In assays performed in vitro, AGPAT4 significantly increased the 
incorporation of [
14
C]oleoyl-CoA into phosphatidic acid using lysophosphatidic acid as an 
acyl acceptor. AGPAT4 did not display significant acyltransferase activity with 
lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylserine, 
lysophosphatidylinositol, lysophosphatidylglycerol, monolysocardiolipin or 
dilysocardiolipin acyl acceptors. Overexpressing AGPAT4 in Sf9 cells increased the total 
phosphatidylinositol content, but did not significantly affect levels of other 
glycerophospholipids, including phosphatidic acid. Analysis of the fatty acyl profile of PA 
from AGPAT4-overexpressing cells indicated increased individual saturated fatty acids, 
particularly lauric acid (C 12:0), and arachidic acid (C 20:0). AGPAT4 localized 
predominately to the mitochondria, and was also regulated during embryogenesis, and in 
varying metabolic states. In summary, this thesis has characterized AGPAT4 as a 
lysophosphatidic acid acyltransferase with a potential role in mitochondrial function.  
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Chapter One – Introduction 
Life is critically dependent on the existence of biological membranes. Present in 
every cell, membranes perform a variety of roles crucial to maintaining a healthy state. 
The plasma membrane is composed of lipids, proteins, and carbohydrates, each with a 
crucial role in membrane function. Phospholipids are a major lipid class found in 
membranes, which form the principle component of the lipid bilayer. Phospholipids are 
amphipathic molecules, containing both polar (phosphate heads) and non-polar (fatty acyl 
tails) regions. Phospholipids that contain a glycerol backbone with fatty acyl chains 
attached are known as glycerophospholipids. Typically, glycerophospholipids are 
esterified with a saturated fatty acid at the sn-1 position, and an unsaturated fatty acid at 
the sn-2 position (1). In addition to these hydrophobic fatty acids, a hydrophilic group is 
attached at the sn-3 position, which, in membranes, usually consists of a phosphate and a 
polar head group (2). Common examples of these polar head groups can be choline, serine, 
or ethanolamine, although others exist. These resultant phospholipid species are then 
known as phosphatidylcholine (PC), phosphatidylserine (PS), or 
phosphatidylethanolamine (PE), respectively.  
 
Specific membranes will have varying compositions of glycerophospholipid 
species from one another, and organellar membranes can differ greatly. The outer 
mitochondrial membrane (OMM) is primarily composed of PC, PE, and 
phosphatidylinositol (PI) (3). The inner mitochondrial membrane (IMM), however, is 
predominated by the glycerophospholipid cardiolipin (CL), which is not present in 
substantial amounts on the OMM (3,4). The unique composition of these membranes is 
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regulated by a number of enzymes, each with their own substrate specificities. These 
enzymes function in the Kennedy Pathway of phospholipid and triacylglycerol de novo 
synthesis, first described by Eugene Kennedy in 1956 (5), and in Lands remodeling 
pathway, first described by W.E. Lands in 1958 (6). The initial composition of de novo 
synthesized phospholipids is primarily defined by the substrate specificities of glycerol-3-
phosphate acyltransferases (GPATs), and acyl-glycerol phosphate acyltransferases 
(AGPATs), which catalyze the first two steps in de novo phospholipid synthesis in the 
classical Kennedy Pathway of glycerolipid biosynthesis. Fatty acyl chain remodeling of 
phospholipids by enzymes in the Land’s pathway, however, can introduce substantial 
variation in the glycerophospholipid species that are ultimately produced.  
The aim of this thesis was to characterize AGPAT isoform 4, which to date had not 
been fully investigated. AGPAT4 mRNA expression was analyzed by real-time reverse 
transcriptase polymerase chain reaction (RT-qPCR) in mouse tissues and by 
immunoblotting of subcellularly fractionated mouse brains. Substrate specificities of this 
enzyme were assessed in vitro through the use of radiochemical assays performed with a 
variety of lysophospholipid acceptors and radiolabelled oleoyl-CoA in the presence of 
lysates from Sf9 cells infected with baculoviral Agpat4. AGPAT4 activity in vivo was 
determined by assessing the fatty acid content of phospholipid fractions from Sf9 cells 
overexpressing AGPAT4. Finally, insight into the physiological role of AGPAT4 was 
examined through mRNA expression during murine embryogenesis and in varying 
metabolic states.  
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Chapter Two – Biochemical Foundations 
The Kennedy Pathway of Phospholipid and Triacylglycerol Synthesis and Lands’ 
Remodeling Pathway 
The Kennedy Pathway (Figure 1) begins with the acylation of glycerol-3-
phosphate (G3P) at the sn-1 position by a member of the GPAT family of proteins, 
forming lysophosphatidic acid (LPA). Mitochondrial GPATs (mtGPATs) prefer to esterify 
saturated fatty acids (7,8). Microsomal GPATs also tend to prefer saturated fatty acids 
although they have shown activity with unsaturated fatty acids as well (7-10). LPA is then 
acylated at the sn-2 position by an AGPAT to form phosphatidic acid (PA). AGPATs vary 
in their substrate preferences (11). A summary of AGPAT motifs in both humans and mice 
is seen in Table 1. Additionally, the amino acid sequence of AGPAT4 for both mice and 
humans is seen in Figure 2. Human and mouse amino acid sequences for AGPAT4 are 
identical in length and 87.8% similar, with 47 mismatched amino acids out of 365 total 
amino acids. Glycerophospholipid fatty acyl specificity begins with the formation of PA, 
but this molecule is a branching point in the Kennedy Pathway. Mitochondrial PA can 
either be used to form mitochondria-associated glycerophospholipids, where it is thought 
to move from the OMM to the IMM for the synthesis of PI, PG, or CL (12) or it can be 
converted into 1,2 – diacylglycerol (DAG), that is a substrate for the formation of 
triacylglycerol (TAG), or other polar glycerophospholipids including PC, PE, and PS.  
 If PA is shunted into the biosynthesis of mitochondria-specific 
glycerophospholipids, it is first dephosphorylated to produce DAG, which is then 
conjugated with cytidine diphosphate to produce cytidine diphosphate-diacylglycerol 
(CDP-DAG). CDP-DAG is then converted into phosphatidylglycerol phosphate (PGP) via 
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the enzyme phosphatidylglycerol phosphate synthase (PGPS), in the first committed step 
of CL biosynthesis (13). Immature CL is formed through the condensation of CDP-DAG 
and PG. It is then subject to remodeling in the Lands pathway (6), just as all 
glycerophospholipids are, through the joint action of a variety of phospholipases A2 
(PLA2) and either acyltransferases or transacylases. There are over a dozen different 
known mammalian PLA2, and they vary widely in substrate specificity, with different 
preferences for glycerophospholipid species and fatty acyl side chain moiety (14-17). 
There are also over a dozen known acyl-CoA-dependent and –independent mammalian 
phospholipid O-acyltransferases, and these tend to show significant acyl donor substrate 
specificity (14,16), and recognize only narrow classes of glycerophospholipid acyl 
acceptor substrates.  
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Figure 1: The Kennedy Pathway of triacylglycerol and glycerophospholipid synthesis. 
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Glycerol-3-phosphate acyltransferases (GPATs)  
 
 The addition of a fatty acyl-CoA to G3P converting it to LPA is the initial step 
performed in the Kennedy Pathway. The enzyme family responsible for this catalytic 
activity is the GPAT family of proteins. To date, four genes encoding for GPAT enzymes 
have been identified, two of which are expressed in the mitochondria. The first GPAT 
identified, known as mitochondrial GPAT 1 (mtGPAT1) was identified and described in 
1993 (7). Expressed in the OMM, mtGPAT1 preferentially esterifies saturated fatty acids, 
and shows specificity for use of palmitoyl-CoA(7). Just over a decade later, the second 
mitochondrial GPAT was identified from rat liver mitochondria, and it was named 
mtGPAT2 (8). Similarly to mtGPAT1, mtGPAT2 is also expressed in the OMM. Unlike 
mtGPAT1 however, mtGPAT2 utilizes both saturated and unsaturated fatty acids equally 
well (8). The first microsomal GPAT, known now as GPAT3 was identified in 2006 (10). 
The second microsomal GPAT was reported in 2008 (9). Both isoforms of the microsomal 
GPATs show some preferential activity with saturated fatty acids, although activity has 
been reported with unsaturated fatty acids as well (9,10).  
1-Acylglycerol-3-phosphate-O-acyltransferases (AGPATs) 
 
 The second committed step of the Kennedy Pathway is the esterification of a fatty 
acyl-CoA onto the sn-2 position of LPA by a member of the AGPAT family of proteins 
that produce PA, a branching point for either TAG or glycerophospholipid synthesis. To 
date, eleven isoforms of AGPATs have been identified in both mice and humans (18-26). 
However, detailed analysis has determined that only a few of these function primarily as 
classical AGPATs utilizing LPA as a major acyl acceptor, while the majority primarily 
exhibit remodeling activity with alternate lysophospholipid species, or else have GPAT 
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activity. This has lead to renaming of many of the AGPAT family members. For example, 
AGPAT6 has been renamed lysophosphatidylethanolamine acyltransferase (LPEAT) 2 
after it was found to primarily utilize lysophosphatidylethanolamine (LPE) as an acyl 
acceptor (18). Likewise, AGPAT8 has been renamed acyl-CoA:lysocardiolipin 
acyltransferase (ALCAT) 1 since it utilizes MLCL and DLCL as acyl acceptors (27). A 
summary of all AGPAT isoform characterizations can be found in Table 2. 
  
 AGPAT1 was the first isoform of the AGPAT family cloned and characterized in 
mice (28). Biochemical specificity of AGPAT1, and later the second isoform identified, 
AGPAT2, were determined through microsomal substrate analysis reporting that both 
isoforms preferentially select oleoyl-CoA (C18:1n-9) as an acyl donor and LPA as the 
major acyl acceptor. In addition, AGPAT1 is also adept in employing odd-chain fatty 
acids (C15:0-CoA) as an acyl donor (29). Both AGPAT1 and AGPAT2 have been shown 
to localize to the endoplasmic reticulum (28-30). Therefore, both isoforms are thought to 
have similar physiological functions due to their identical substrate specificities and 
subcellular localization (28). AGPAT1 was shown to have highest expression in testis, 
with some expression in pancreas and adipose tissue, but is expressed in a broad range of 
tissues (19), whereas AGPAT2 was predominately expressed in adipose tissue, with some 
expression in liver and pancreas (29). 
 Both AGPAT3 and APGAT5 have been reported to localize to the endoplasmic 
reticulum, as well as the nuclear envelope, while AGPAT5 also localized to the 
mitochondria (25). AGPAT3 preferentially esterifies LPA in the presence of arachidonic 
acid (C20:4n-6), but will also use LPE in the presence of oleoyl-CoA (25,31). AGPAT3 
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has been shown to have high expression within testis (31), pancreas, and kidney (25). 
AGPAT5 tissue expression has been found to be high in skeletal muscle and heart, with 
low expression in the prostate and testis (25). 
 AGPAT6 and AGPAT7 have also been shown to localize to the endoplasmic 
reticulum (20,21). AGPAT6 preferentially uses saturated fatty acyl-CoAs including 
C12:0-CoA, C16:0-CoA, and C18:0-CoA (20), but does not show a preference for a 
lysophospholipid acceptor whereas AGPAT7 prefers longer-chain fatty acids including 
C16:0-CoA, C18:0-CoA, C18:1n-9-CoA (18). Oleoyl-CoA is the preferred acyl donor of 
AGPAT7, and LPE is the preferred acyl acceptor (18). AGPAT6 has been reported to have 
broad distribution within tissues, and is important in overall AGPAT activity (20). 
AGPAT7 showed predominant expression within brain, and is thought to have a role in 
phospholipid remodeling of PE (20). 
 AGPAT8 is predominately expressed in heart and localizes to the endoplasmic 
reticulum. It utilizes palmitoyl-CoA to esterify into LPA over both oleoyl-CoA, and 
stearoyl-CoA (22). AGPAT8 has also been shown to utilize both MLCL and DLCL to 
produce CL, which is its primary function in vivo (27). AGPAT9 shows predominant 
expression in lung and spleen, and was shown to prefer oleoyl-CoA as a fatty acyl donor, 
with LPA as the acyl acceptor (24). At the cellular level, AGPAT9 localizes to the 
endoplasmic reticulum, and has similar AGPAT enzymatic activity as AGPAT3, 
AGPAT5, and AGPAT8 (24).  
 Both AGPAT10 and AGPAT11 localize to the endoplasmic reticulum (23,26). 
AGPAT10 is more highly expressed in adipose tissue, followed by the testis, and kidney 
(26), whereas AGPAT11 is found to be predominately expressed in heart and skeletal 
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muscle (23). Both AGPAT10 and AGPAT11 utilize oleoyl-CoA to esterify into LPA 
(23,26). 
 
Table 1: Summary of AGPAT protein family conserved motifs. 
Motif 
Number 
Motif Mouse AGPAT4 Human AGPAT4 
Encodes 
for 
Reference 
I NHX4D 
93 
VLNHKFEIDFLCG 
93 
VLNHKFEIDFLCG 
Catalysis (32) 
II FX2R 
139  
VEMIFCTRKW 
139  
TEMVFCSRKW 
G3P 
Binding 
(32) 
III EGTR 
173  
IHCEGTRFT 
173  
IHCEGTRFT 
G3P 
Binding 
(32) 
IV P 
202 
HHLLPRTKGFA 
202 
HHLLPRTKGFA 
Catalysis (32) 
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Table 2: Summarized results of AGPAT family member tissue and subcellular expression, substrate preferences, and enzyme 
classifications. 
AGPAT 
Isoform 
Tissue Expression 
Subcellular 
Localization 
Fatty acyl-
CoA donor 
Lysophospholipid acceptor Other name(s) References 
1 
Testis, pancreas, 
adipose tissue 
Endoplasmic reticulum 
C18:1-CoA 
C15:0-CoA 
LPA LPAAT-α (28,29) 
2 
Adipose tissue, 
pancreas, liver 
Endoplasmic reticulum C18:1-CoA LPA LPAAT-β (29) 
3 
Testis, pancreas, 
kidney 
Endoplasmic reticulum, 
Nuclear envelope 
C20:4-CoA LPA, LPC/LPI/LPS LPAAT-γ (25,31) 
4 
Brain, heart, renal 
WAT, present in 
most tissues 
Mitochondria 
C12:0-CoA 
C18:0-CoA 
C20:0-CoA 
 
In vitro: LPA 
In vivo: LPI 
LPAAT-δ (19,25,33) 
5 Skeletal muscle, heart 
Endoplasmic reticulum, 
mitochondria 
C18:1-CoA LPA, LPE LPAAT-ε (25) 
6 
Liver, broad 
distribution 
Endoplasmic reticulum 
C16:0-CoA 
C18:1n-9-CoA 
C18:2n-6 
 
No specificity 
GPAT4 
LPAAT-ζ 
(10,20,34) 
7 Brain Endoplasmic reticulum C18:1-CoA LPE 
LPEAT2, 
LPCAT4, 
LPAAT-η 
 
(18,21) 
8 Heart Endoplasmic reticulum C16:0-CoA LPA, LPC, MLCL, DLCL 
ALCAT1, 
LPCAT1 
 
(22,27) 
9 Lung, spleen Endoplasmic reticulum C18:1-CoA LPA 
 
 
(24) 
10 Adipose tissue Endoplasmic reticulum C18:1-CoA LPA 
LPAAT-θ 
GPAT3 
(26) 
11 Heart, skeletal muscle Endoplasmic reticulum C18:1-CoA LPA  (23) 
Abbreviations: 1-acylglycerol-3-phosphate O-acyltransferase (AGPAT), white adipose tissue (WAT), lysophosphatidic acid (LPA), 
lysophosphatidylcholine (LPC), lysophosphatidylinositol (LPI), lysophosphatidylserine (LPS), monolysocardiolipin (MLCL), 
dilysocardiolipin (DLCL), lysophosphatidylethanolamine (LPE), lysophosphatidic acid acyltransferase (LPAAT), acyl-
CoA:lysocardiolipin acyltransferase (ALCAT), glycerol-3-phopshate acyltransferase (GPAT), lysophosphatidylcholine acyltransferase 
(LPCAT), lysophosphatidylethanolamine acyltransferase (LPEAT). 
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AGPAT4 
 
 AGPAT4 has also been identified in both humans and mice, although 
characterization work on this enzyme has been limited until recently. Lu et al. (2005) 
reported that recombinant AGPAT4 synthesized in reticulocyte lysates had shown a low 
level of AGPAT activity with LPA (19). In the same study, however, murine AGPAT4 
was expressed in COS-7 cells transfected with the mammalian expression vector 
pcDNA3.1-AGPAT4, and AGPAT activity was not consistently observed (19). Recently, 
the work of Eto et al. (2014) characterized AGPAT4 activity as an AGPAT, which 
preferentially esterifies docosahexanoic acid (DHA) into LPA in CHO-K1 cells in vitro 
(33). A significant limitation of this work is that it only included use of LPA as an acyl 
acceptor, and no other lysophospholipids were assayed, including mitochondrial-
associated lysophospholipids including lysophosphatidylinositol (LPI), MLCL, and 
DLCL. In addition, only the microsomal fraction was utilized for activity assays, 
precluding analysis of the mitochondrial fraction that we have found contains the majority 
of AGPAT4 localization. The inconsistent AGPAT activity shown in these reports, along 
with a lack of literature characterizing this isoform with other acyl acceptors, was the basis 
of this thesis project.  
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Figure 2: Amino acid sequence alignment of mouse (Mus musculus: GI 28704097) 
and human (Homo sapiens: GI 69128030) 1-acyl-glycerol-3-phosphate O-
acyltransferase 4. 
Sequences display 87.8% identity (46 mismatched amino acids), and identical chain 
lengths. Predicted substrate binding and catalytically active motifs are displayed in bold, 
with critical residues underlined. Predicted transmembrane helices are represented in grey 
italics.  
Mm       1 MDLIGLLKSQ FLCHLVFCYV FIASGLIVNA IQLCTLVIWP INKQLFRKIN ARLCYCVSSQ  60 
  MDLIGLLKSQ FLCHLVFCYV FIASGLIVNA IQL TL  WP INKQLFRKIN  RL YC SSQ 
Hs       1 MDLAGLLKSQ FLCHLVFCYV FIASGLIINT IQLFTLLLWP INKQLFRKIN CRLSYCISSQ  60 
 
 
            Motif I 
Mm      61  LVMLLEWWSG TECTIYTDPK ACPHYGKENA IVVLNHKFEI DFLCGWSLAE RLGILGNSKV  120 
  LVMLLEWWSG TECTI TDP  A   YGKENA IVVLNHKFEI DFLCGWSL E R G LG SKV 
Hs      61  LVMLLEWWSG TECTIFTDPR AYLKYGKENA IVVLNHKFEI DFLCGWSLSE RFGLLGGSKV  120  
 
 
        Motif II       Motif III 
Mm     121  LAKKELAYVP IIGWMWYFVE MIFCTRKWEQ DRQTVAKSLL HLRDYPEKYL FLIHCEGTRF  180 
  LAKKELAYVP IIGWMWYF E M FC RKWEQ DR TVA SL  HLRDYPEKY  FLIHCEGTRF    
Hs     121 LAKKELAYVP IIGWMWYFTE MVFCSRKWEQ DRKTVATSLQ HLRDYPEKYF FLIHCEGTRF  180 
      
 
        Motif IV 
Mm     181  TEKKHQISMQ VAQAKGLPSL KHHLLPRTKG FAITVKCLRD VVPAVYDCTL NFRNNENPTL  240 
  TEKKH ISMQ VA AKGLP L KHHLLPRTKG FAITVK LR  VV AVYDCTL NFRNNENPTL 
Hs     181 TEKKHEISMQ VARAKGLPRL KHHLLPRTKG FAITVRSLRN VVSAVYDCTL NFRNNENPTL  240 
   
 
Mm     241  LGVLNGKKYH ADCYVRRIPM EDIPEDEDKC SAWLHKLYQE KDAFQEEYYR TGVFPETPWV  300 
  LGVLNGKKYH AD YVRRIP  EDIPED D C SAWLHKLYQE KDAFQEEYYR TG FPETP V 
Hs     241  LGVLNGKKYH ADLYVRRIPL EDIPEDDDEC SAWLHKLYQE KDAFQEEYYR TGTFPETPMV  300 
 
Mm     301  PPRRPWSLVN WLFWASLLLY PFFQFLVSMV SSGSSVTLAS LVLIFCMASM GVRWMIGVTE  360 
  PPRRPW LVN WLFWASL LY PFFQFLVSM   SGSS TLAS   L F  AS  GVRWMIGVTE 
Hs     301  PPRRPWTLVN WLFWASLVLY PFFQFLVSMI RSGSSLTLAS FILVFFVASV GVRWMIGVTE  360 
 
Mm     361  IDKGSAYGNI DNKRKQTD 378           
  IDKGSAYGN  DNK K  D 378 
Hs     361  IDKGSAYGNS DSKQKLND 378 
	
	
	
Supplementary Fig. 1. Amino acid sequence alignment of mouse (Mus musculus: GI 28704097) and human 
(Homo sapiens: GI 69128030) 1-acyl-glycerol-3-phosphate O-acyltransferase 4 (ALCAT2). Sequences display 
87.8% identity (46 mismatched amino acids), and identical chain lengths. Predicted substrate binding and 
catalytically active motifs are displayed in bold, with critical residues underlined. Predicted transmembrane 
helices are represented in grey italics. 
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Figure 3: Kyte-Doolittle hydropathy plot of murine (Mus musculus: GI 28704097) 
AGPAT4 indicating from 3-5 possible transmembrane helices.  A, a proposed K-D plot 
of AGPAT4). Murine 1-acyl-glycerol-phosphate O-acyltransferase 4 is 378 amino acids in 
length, with three strongly predicted transmembrane helices. From the N-terminus, 
AGPAT4 is cytosolic from the first to 19
th
 amino acid. The 20
th
 to 42
nd
 amino acids span 
the mitochondrial membrane, while a large bulk of the protein (43
rd
 to 307
th
 amino acids) 
is inside the mitochondrial membrane. Twenty three amino acids (308-330) span the 
mitochondrial membrane, with a small 3 amino acid fragment becoming cytosolic once 
again (331-334). The protein then spans back down into the membrane from the 335
th
 to 
357
th
 amino acids, once more entering the inner membrane space from the 358
th
 to 378
th
 
amino acid. B, two other proposed K-D plots of AGPAT4. A strongly preferred model 
indicates 5 transmembrane helices, while an alternative model suggests 4 transmembrane 
helices. 
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Chapter Three – Rationale, Objectives, and Hypotheses 
Rationale 
 
AGPAT4 had not been fully characterized. Although two studies have been published 
on this protein (19,33), one prior to our work (in 2005), and the other in 2014 during the 
course of our studies on AGPAT4, results were ambiguous. The study by Lu et al. (2005) 
failed to find AGPAT activity for APGAT4 in COS-7 cells although the authors did detect 
it in reticulocyte lysates (19), while the report by Eto et al. (2014) may have excluded the 
major acyltransferase activity of this enzyme by failing to investigate activity in the 
mitochondrial fraction, or activity with lysophospholipid acceptors other than LPA (33). 
Based on high sequence homology to other members of the AGPAT superfamily, it 
seemed highly likely that AGPAT4 would localize to the endoplasmic reticulum and 
function in phospholipid synthesis and remodeling (Table 2). Prior to our work, however, 
it had not yet been determined experimentally what specific activity AGPAT4 had, or 
where it localized within cells or within the brain. At the initiation of this project, we 
believed that AGPAT4 could be a lysophosphatidic acid acyltransferase (LPAAT), a 
lysophosphatidylcholine acyltransferase (LPCAT), a LPEAT, a lysophosphatidylserine 
acyltransferase (LPSAT), a lysophosphatidylinositol acyltransferase (LPIAT), a 
lysophosphatidylglycerol acyltransferase (LPGAT), an acyl-CoA:lysocardiolipin 
acyltransferase (ALCAT), a GPAT, or have a combination of these functions. We also 
believed that it could have microsomal, mitochondrial, nuclear, or some other subcellular 
localization. A role in lipid biosynthesis suggests that this enzyme would be down-
regulated during fasting, which is a predominantly catabolic state. 
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Objectives 
 
The objectives of my thesis were to characterize AGPAT4 tissue expression, 
subcellular localization, and in vitro and in vivo activity, and to perform preliminary 
investigation of a physiological role for this enzyme by determining expression at various 
embryonic timepoints and during changing nutritional states.  
My first objective was to determine the expression of AGPAT4 at the tissue level. 
Agpat4 mRNA from a variety of murine tissues was assessed for predominate expression, 
and immunohistochemistry was used to detect AGPAT4 in a mixed primary neural cell 
culture.  
My second objective was to determine the predominate localization of this enzyme at 
the subcellular level. This was determined by fluorescence microscopy of HEK-293 cells 
overexpressing an AGPAT4-GFP chimera, and was confirmed by immunoblot analysis of 
fractionated mouse brain assessing endogenous AGPAT4.  
My third objective was to assess the biochemical activity of AGPAT4. Protein lysates 
from Sf9 cells overexpressing AGPAT4 were reacted with a variety of lysophospholipid 
acceptors in the presence of a mixture of unlabeled and radiolabeled fatty acyl-CoAs in a 
radiochemical enzyme assay performed in vitro. In vivo activity was assessed by gas 
chromatography (GC) quantification of fatty acids in specific phospholipid species 
resolved by thin layer chromatography (TLC) from Sf9 cells overexpressing AGPAT4.  
My fourth objective was to investigate potential developmental and physiological roles 
for AGPAT4 by quantification of gene expression during different murine embryonic 
stages (E10.5, E14.5, E18.5), and in varying nutritional states (non-fasted, fasted, and 
refed) in a variety of murine tissues.  
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Hypotheses 
The hypotheses of this study were: 
 
1. AGPAT4 is an acyl-CoA-dependent lysophospholipid acyltransferase. 
2. AGPAT4 will be most highly expressed in the brain. 
3. AGPAT4 will localize to the endoplasmic reticulum. 
4. AGPAT4 gene expression will be down-regulated during the fasted metabolic state 
as compared to the non-fasted and refed states. 
5. AGPAT4 gene expression will be up-regulated during early murine 
embryogenesis. 
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Chapter Four – Methods 
Animals 
 Three to four-month old female C57B/6 mice were housed in a temperature and 
humidity controlled environment, on a 12:12 hour reversed light/dark cycle. Where 
possible, littermates were used. Standard rodent chow was provided ad libitum unless 
otherwise specified (i.e. metabolic experiments). All animal procedures were approved by 
the University of Waterloo Animal Care Committee.  
Cloning of Full-length AGPAT4 cDNA, AGPAT4-GFP, and Generation of AGPAT4 
Baculovirus and Protein in Sf9 Cells 
 
Full length murine AGPAT4 was amplified by PCR from mouse whole brain 
cDNA with the addition of BglII and SalI restriction sites to the N-terminal and C-terminal 
ends, respectively, using the following primers: forward 5’-AGA TCT ACC ATG GAC 
CTC ATC GGG CTG-3’ and reverse 5’-CGT CGA CTT GTC CGT TTG TTT CCG TTT 
G-3’. The resulting amplicon was subcloned into pGEM-T-Easy resulting in production of 
pGEM-AGPAT4 that was verified by direct sequencing, and was then cut with BglII/SalI 
restriction enzymes for directional subcloning into pEGFP-N1 in frame with green 
fluorescent protein (GFP). Baculovirus was generated using the Bac-to-Bac® Baculovirus 
Expression System. A full length AGPAT4 amplicon with a C-terminal 6 x His tag and 
BglII and SalI restriction sites at the N-terminal and C-terminal ends was produced by 
PCR using 50 ng of pGEM-AGPAT4 as template and the following primers: forward 5’-
AGA TCT ACC ATG GAC CTC ATC GGG CTG-3’; reverse 5’-GTC GAC GTG GTG 
GTG GTG GTG GTG GTC CGT TTG TTT CCG TTT GTT GTC G-3’. The resulting 
amplicon was subcloned into pGEM-T-Easy for direct sequencing, forming pGEM-
AGPAT4-6His. This vector was subsequently digested using NotI/SalI to release full-
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length AGPAT4 that was subcloned into NotI/SalI restriction sites in pCMV-3Tag-3A, 
which was then digested with KpnI/NotI releasing full-length AGPAT4 that was 
subcloned in frame with the 3x HA tag into pFastBacI. pFastBacI-AGPAT4 was 
transformed into DH10Bac chemically competent cells and plated on triple selection 
(Kanamycin, Gentamicin, Ampicillin) LB plates treated with Xgal and IPTG. Positive 
white colonies were prepped, verified by direct sequencing, and transfected into Sf9 cells 
grown in Sf-900 III media, and incubated for 3-4 days to generate baculovirus. Control 
baculovirus was produced by the same method but using pFastBacI without DNA 
insertion into the multiple cloning site. Amplified baculovirus was titred by serial dilution 
in cultures of Sf9 cells grown in 6-well plates, and harvested at 70-80% viability indicated 
by staining a subset of cells with trypan blue visualized by light microscopy. Infected Sf9 
cells were harvested, and lysed in Lysis Buffer 1 (100mM Tris-HCl, pH 7.4, 5mM NaCl, 
3mM MgCl2) by sonication on ice (65% output, 3 x 6 s), which efficiently disrupts 
mitochondria and other organelles. Unbroken cells and organelles, and cellular debris were 
cleared by centrifugation (10,000  g for 10 min). This process will pellet any remaining 
unbroken mitochondria, but not submitochondrial particles generated by sonication. 
Protein in supernatants was quantified using Bradford assay solution and diluted to 1 
μg/μL for use in radiochemical assays or western blotting.  
Cell Culture and Primary Neural Culture 
 
HEK-293 cells were maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin, and 
routinely subcultured upon reaching 90% confluence by trypsinization with 0.25% trypsin-
EDTA. For primary neural cultures, fetal mice at embryonic d17.5 – 18.5 were decapitated 
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in a cell culture dish on ice containing dissection media (HBSS with 30mM HEPES, 0.6% 
w/v glucose, 2% w/v sucrose, final pH 7.4). Brains were dissected out and transferred to a 
15 mL conical tube, washed 3  with ice-cold dissection media, and the cortex was 
separated then incubated with 2 mL of pre-warmed 0.25% trypsin-EDTA for 20 minutes at 
37°C in a humidified cell culture incubator with 5% CO2. Post incubation, cells were spun 
at 1000  g for 5 min, trypsin was removed, and samples were washed once with warm 
dissection media. Brain samples were then re-suspended by pipetting in 2 mL of warm 
plating media (DMEM/F12 + 10% horse serum + 10% FBS + 1% penicillin-streptomycin) 
until a homogenous mixture was achieved. The homogenate was strained using a 100 μm 
nylon cell strainer into a 50 mL conical tube, and centrifuged at 1000  g for 5 minutes at 
4°C. The pellet, containing mixed cortical neurons and glial cells, was re-suspended in 2 
mL of plating media, and cells were seeded onto glass coverslips pretreated with poly-D-
lysine and incubated at 37°C with 5% CO2 for 3 hours. Once cells had attached to the 
plate, 50% of plating media was removed, and supplemented with feeding media 
(Neurobasal media + 1% B27 supplement) to support the differentiation of primary 
neurons. 
RNA Extraction, Reverse Transcription (RT) PCR, and RT qPCR 
 
Whole-embryos and mouse organs were collected and flash frozen in liquid 
nitrogen at the Central Animal Facility at the University of Waterloo. Total RNA was 
isolated from tissues using TRIzol® Reagent (1 mL/≤100 mg tissue) and a Polytron® 
homogenizer (VWR, Radnor PA) set at the highest speed. Samples were then incubated at 
room temperature for 5 minutes, followed by the addition of chloroform (20% of TRIzol® 
volume) with vigorous shaking for 15-20 seconds, incubation at room temperature for 2 
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minutes, and centrifugation at 12,000 x g for 15 minutes at 4°C. The upper aqueous phase 
of each sample was removed and mixed with isopropanol (50% of initial volume of 
TRIzol®), and incubated at room temperature for 10 minutes to precipitate the RNA. 
Samples were then centrifuged at 12,000 x g for 10 minutes at 4°C, pelleting the RNA. 
The supernatant was discarded and the pellet was washed in 1 mL of 75% ethanol-25% 
DEPC water, centrifuged at 7,500 x g for 5 minutes at 4°C, then air-dried for 5-10 minutes 
prior to suspension in 50 μL DEPC-ddH2O. The solution was then incubated at 58°C for 
12 minutes to facilitate solubilization, and stored long-term at -80°C. RNA samples were 
quantified using a Nanodrop 2000 Spectrophotometer (Thermo Scientific, Waltham MA), 
and samples were adjusted to 2 μg/μL. cDNA was synthesized from 2 μg of RNA by 
oligo(dT) priming using SuperScript II Reverse Transcriptase according to the 
manufacturer’s protocol. Briefly, 2 μg of RNA was mixed with 1 μL of 10 mM dNTPs and 
1μL of oligo(dTs)12-18 and incubated at 65°C for 5 minutes in a denaturation step, cooled 
briefly on ice (1-2 minutes), then mixed with 6 μL of reaction mix (consisting of 4 μL of 
5X first strand buffer, 2 μL 0.1M DTT) and incubated at 42°C for 2 minutes to allow for 
primer annealing. Finally, 80 units of Superscript II Reverse Transcriptase were added to 
each sample and cDNA synthesis was allowed to proceed at 42°C for 50 minutes with 
termination of reactions by incubation at 70°C for 15 minutes. cDNA was stored at -80°C. 
Tissue-specific expression of Agpat4 was determined using 1 μL of cDNA amplified by 
PCR using the primers: forward Agpat4 5’-ATG GAC CTC ATC GGG CTG CTG-3’, 
reverse Agpat4 5’- GTC CGT TTG TTT CCG TTT GTT GTC G-3’ (1133 bp amplicon) 
and forward 36B4 5’-CAG CAG GTG TTT GAC AAC GG-3’, reverse 36B4 5’-TGG 
TTG CTT TGG CGG GAT TA-3’ (404 bp amplicon) or by Taqman gene expression 
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assays (Mm00509777_m1 for Agpat4 and Mm04277571_s1 for 18S) in a CFX-96 
Connect Real Time PCR Detection System (BioRad, Hercules CA). The thermal cycling 
protocol was as follows: One cycle of 95°C for 5 minutes, 40 cycles at 95°C for 15 
seconds, then 60°C for 30 seconds. Gene expression levels were normalized to 18S and 
quantified by the ΔΔCt method. 
 
In vitro acyl-CoA:lysophospholipid acyltransferase assay and thin layer chromatography 
 
A substrate mixture containing 80 μM lysophospholipid, 200 μM oleoyl-CoA, and 
[
14
C]oleoyl-CoA (0.025 μCi per reaction) was prepared, dried under a stream of N2 and 
reconstituted in reaction buffer (100 mM Tris, pH 7.0, 4 mg/mL BSA) by vortexing at 
high speed for 30 s. Reactions were initiated by addition of 100 μL of pre-warmed 
substrate mixture to 100 μL of sonicated, cleared lysates from Sf9 cells infected with 
either AGPAT4 or control baculovirus, prepared as described above. Reactions were 
mixed gently, and incubated in a 37°C water bath for 30 min, then quenched by addition 
of 0.75 mL of methanol:chloroform (2:1, v/v). Lipids were extracted by the method of 
Bligh & Dyer (35). Briefly, quenched reactions were mixed with 0.25 mL of chloroform, 
vortexed thoroughly, mixed with 0.25 mL of ddH2O, vortexed again, then centrifuged at 
1000  g for 5 minutes to separate aqueous (upper) and organic (lower) phases. The 
organic phase was recovered and dried under a stream of N2. Samples were reconstituted 
in 50 μL of chloroform, applied to a silica gel G plate, and resolved by TLC using a 
hexane:diethyl ether:glacial acetic acid solvent system (80:20:2, v/v/v). The band 
corresponding to phospholipids was scraped and extracted from silica by the addition of 
0.75mL of methanol:chloroform, upon which a further lipid extraction by the method of 
Bligh & Dyer followed. The organic phase was recovered and dried under a stream of N2. 
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Samples were reconstituted in 50 μL of chloroform, applied to a silica gel H plate, and 
resolved by polar lipid TLC using a chloroform:methanol:2-propanol:0.25% 
KCl:triethylamine solvent system (30:9:25:6:18, v/v/v/v/v). Phospholipid species were 
identified by known standards, and corresponding bands were scraped and quantified by 
liquid scintillation counting. 
In vivo phospholipid fatty acid analysis 
 
Sf9 cells grown in 250 mL flasks were infected with either control or AGPAT4 
baculovirus. Seventy-two hours later, cells were harvested by gentle aspiration into 50 mL 
concial tubes. A subset of the cells (1 mL) was lysed for extraction and quantification of 
protein, while another subset (1 mL) was extracted by the method of Folch using 2:1 (v/v) 
chloroform:methanol with butylated hydroxytoluene as an antioxidant (Sigma-Aldrich, 
Bellfonte PA), and subsequent addition of sodium phosphate (36). The organic phase was 
applied to a silica gel H plate and resolved by TLC on a chloroform:methanol:2-
propanol:0.25% KCl:triethylamine solvent front (30:9:25:6:18, v/v/v/v/v). Bands 
corresponding to individual phospholipid species were identified using known standards, 
overlaid with 10 μg of 22:3n-3 ethyl ester internal standard (Nu-Check Prep, Elysian, 
MN), and scraped for determination of fatty acid composition and content by gas 
chromatography with flame ionization detection as previously described (37). Briefly, 
fatty acid methyl esters were derivatized by transesterification using 14% boron trifluoride 
in methanol (Thermo Scientific, Bellfonte PA) with hexane on a 95°C heat block for 1 h. 
Fatty acid methyl esters were analyzed on a Varian 3900 gas chromatograph equipped 
with a DB-FFAP 15 m x 0.10 mm injected dose x 0.10 μm film thickness, 
nitroterephthalic acid modified, polyethylene glycol, capillary column (J&W Scientific 
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from Agilent Technologies, Mississauga, Ontario, Canada) with hydrogen as the carrier 
gas. Samples (2 μL) were introduced by a Varian CP-8400 autosampler into the injector 
heated to 250°C with a split ratio of 200:1. Initial temperature was 150°C with a 0.25-
minute hold followed by a 35°C/minute ramp to 200°C, an 8°C/minute ramp to 225°C 
with a 3.2-minute hold, and then an 80°C/minute ramp up to 245°C with a 15-minute hold 
at the end. The flame ionization detector temperature was 300°C with air and nitrogen 
make-up gas flow rates of 300 and 25 mL/min, respectively, and a sampling frequency of 
50 Hz (37).  
Subcellular fractionation 
 
Subcellular fractions were separated as previously described (38), with minor 
modifications. Briefly, mouse brains were harvested and homogenized at 1,000 rpm in 
buffer A (250 mM Sucrose, 50 mM Tris-HCl, pH 7.4, 5 mM MgCl2), then centrifuged at 
800  g for 15 min to isolate the nuclear fraction. All centrifugation steps were performed 
at 4°C. Post-nuclear supernatants were removed to a fresh tube on ice for further 
processing. The nuclear pellet was washed twice by re-suspending in 300 μL of buffer A, 
with added protease and phosphatase inhibitor cocktails, followed by 15 min 
centrifugations at 500  g, then 1000  g. The final pellet was re-suspended in 300 μL of 
buffer B (20 mM HEPES pH 7.9, 1.5 mM MgCl2, 0.5 M NaCl, 0.2 mM EDTA, 20% (v/v) 
glycerol, and 1% Triton X-100), incubated on ice for 30 min, then sonicated into 
homogenous suspension while held in an ice bath using three pulses at 65% output for 6 s 
with a 30 s cooling period in between pulses. Sonicated nuclei were spun at 9000  g for 
30 min to pellet debris, and the supernatant containing the nuclear fraction was recovered. 
Post-nuclear supernatants from the initial lysis and centrifugation of cells were spun at 
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11,000  g for 10 min to pellet mitochondria. The post-mitochondrial supernatant was 
removed to a fresh tube and centrifuged for 1 h at 100,000  g to isolate the microsomal 
fraction, following which the cytosolic supernatant was discarded, and the pellet was re-
suspended in 50 μL of buffer C (50mM Tris-HCl, pH 6.8, 1 mM EDTA, and 0.5% Triton 
X-100) by brief suspension of tubes in an ice-cold sonicating water bath. The 
mitochondrial pellet was resuspended in 100 μL of buffer C and sonicated with three 6 s 
bursts at 65% output in an ice water bath, with a 30 s cooling period between pulses. 
Immunoblotting 
 
Protein lysates were mixed with 2  Laemmeli Buffer (125 mM Tris-HCl, pH 6.8, 
20% glycerol, 4% SDS, 10% 2-mercaptoethanol, and 0.05% bromophenol blue) and 
denatured by heating to 95°C for 5 min. Samples were electrophoresed on 12% SDS-
PAGE gels at 100V for 1 h, and transferred to nitrocellulose membranes at 350A for 90 
minutes to be used for immunodetection. Membranes were blocked for 1 h with 5% skim 
milk powder (w/v) in TBST (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-20), 
then probed overnight in TBST with 1% skim milk powder (w/v) using primary antibodies 
(1:1000 dilution) directed against AGPAT4 (Sigma Aldrich, St. Louis MO), 
CYTOCHROME C, SCD1 (Cell Signalling, Beverly MA), or HISTONE H3 (EMD 
Millipore, Billerica MA). Bands were detected by incubation of blots with HRP-
conjugated anti-mouse or anti-rabbit secondary antibodies followed by enhanced 
chemiluminescence.  
Immunofluorescence 
 
For studies on subcellular localization, HEK-293 cells were grown on coverslips, 
then transfected with pEGFP-N1 (control vector) or chimeric pEGFP-AGPAT4, with or 
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without pDSRed2-Mito (Life Technologies, Carlsbad CA), using Lipofectamine® 2000 
according to the manufacturer’s instructions. Forty-eight hours later, cells that were not 
transfected with pDsRed2-Mito were stained with ER-Tracker™ Red (Life Technologies, 
Carlsbad CA) diluted 1:10,000 in Hank’s Buffered Salt Solution (HBSS), pH 7.1, for 30 
min at 37°C and 5% CO2. Cells were washed twice with HBSS and fixed with 4% 
paraformaldehyde for 10 min, then nuclei were counter-stained with 1 μg/mL diamidino-
2-phenylindole (DAPI) for 15 minutes. Samples were washed again in PBS prior to 
mounting on glass microscope slides using Prolong Antifade mounting medium (Life 
Technologies, Carlsbad CA). Cells were visualized with an Axio Observer Z1 microscope 
equipped with Axio Cam HRm camera and Axiovision Software (Carl Zeiss). 
 
Primary embryonic neurons and glial cells were isolated and grown on coverslips 
pretreated with poly-D-lysine, then fixed with 4% paraformaldehyde for 10 min, washed 
with PBS, and permeabilized with 0.5% Triton X-100 for 5 min at room temperature. 
Cells were then washed with PBS and blocked with 5% goat IgG serum in PBS. After 1 h, 
blocking serum was removed, and cells were incubated at room temperature for an 
additional hour with rabbit anti-AGPAT4 antibody (Bioss, Woburn MA), diluted 1:100 in 
PBS, alone or in combination with mouse anti-GFAP (1:500 dilution) or mouse anti-
NESTIN antibodies (1:500 dilution) (Cell Signaling, Danvers MA). Cells were then 
washed with PBS, and incubated for 1 h at room temperature with Alexa Fluor® 555-
conjugated anti-rabbit IgG, and/or Alexa Fluor® 488-conjugated anti-mouse IgG (Cell 
Signaling, Danvers MA), or stained with Neurotrace® 500/525 Green Fluorescent Nissl 
Stain (1:100 dilution in PBS) for 20 min at room temperature according to the 
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manufacturer’s protocol (Life Technologies, Carlsbad CA). Cells were then washed 
repeatedly with 0.1% Triton X-100 in PBS followed by PBS alone, stained with DAPI (1 
μg/mL) for 15 min, and mounted on glass microscope slides using Prolong Antifade. 
 
Statistical Analysis 
 
The results are expressed as means ± S.E.M. Statistically significant differences 
between two groups were assessed by Student’s t test. Differences between multiple 
groups were assessed by one-way analysis of variance with Bonferroni’s post hoc test. 
Significance is accepted at P < 0.05. 
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Chapter Five – Results 
Agpat4 is highly expressed in brain 
 
Figure 4: AGPAT4 is highly expressed in multiple brain regions. A, representative 
ethidium bromide agarose gel showing AGPAT4 mRNA expression measured by RT-PCR 
in multiple tissues including whole brain. B, AGPAT4 mRNA expression determined by 
qPCR in multiple regions of the central nervous system (n-3). 
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Figure 5: AGPAT4 is highly expressed in neuronal and astroglial cells. Representative 
images showing immunodetection of AGPAT4 in cultured primary cortical neurons and 
glial cells. Primary neurons were identified by positive detection of the neuron-specific 
protein NESTIN, or by co-staining with green fluorophore-labeled Nissl stain. Astroglial 
cells were identified by the detection of the glial marker GFAP. 
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The tissue distribution of Agpat4 mRNA was analyzed and, as expected (19,25,33), 
was found to be highly expressed in mouse whole brain homogenates (Fig. 4A). Agpat4 
was also present at variable levels in all other tissues examined including liver, kidney, 
lung, heart, renal white adipose tissue (WAT), and skeletal muscle. Dissection of mouse 
brains to isolate olfactory bulbs, hippocampus, cerebellum, cortex, brain stem, and the 
remaining brain tissue, followed by RNA preparation and RT-qPCR analysis indicated 
only a small variation in Agpat4 expression within major regions of the central nervous 
system, with no significant differences between regions (Fig. 4B).  
To determine whether AGPAT4 is expressed in neurons or in glial cells, or in both 
cell types, we performed immunohistochemistry on mixed cultures of primary cortical 
neural cells derived from brains of d18.5 embryonic mice. Cells were grown on coverslips 
for 7 days in Neurobasal® medium with B27 supplementation to promote neuronal 
differentiation. Primary neurons were identified as cells expressing the neuron-specific 
intermediate filament NESTIN, or cells positively co-staining with the fluorescent green 
Nissl stain Neurotrace 500/525®. Glial cells were identified as cells expressing glial 
fibrillary acidic protein (GFAP). AGPAT4 showed a diffuse, punctate staining (Fig. 5), 
and was found to co-localize in cells that were identified as positive for either Nissl stain 
or immunodetectable NESTIN, indicating the presence of this enzyme in primary cortical 
neurons (Fig. 5). AGPAT4 was also detected, albeit at a somewhat lower intensity, in cells 
that co-expressed GFAP, indicating that is also found in astroglial cells. 
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AGPAT4 localizes to the mitochondria 
 
 
Figure 6: AGPAT4 localizes predominately to the mitochondria. A, Mouse brains were 
harvested and subjected to differential centrifugation to separate nuclear, mitochondrial, 
and microsomal fractions. Purity of the fractions was determined by immunoblotting for 
markers of mitochondria (CYTOCHROME C), endoplasmic reticulum (SCD1), and nuclei 
(HISTONE H3). B, HEK-293 cells were transfected with pEGFP-N1 (control) or 
AGPAT4 and co-transfected with pDsRed2-Mito, or stained with ER Tracker™ Red dye, 
then imaged by confocal microscopy. 
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To determine the predominant subcellular localization of AGPAT4, mouse brains 
were harvested and subjected to differential centrifugation. Immunoblot analysis for 
AGPAT4 indicated predominate detection of this protein in the mitochondrial fraction 
(Fig. 6), with a faint band apparent in the nuclear fraction, but essentially no AGPAT4 
detectable in the microsomal fraction. Fractional purity was assessed by immunoblotting 
for the mitochondrial protein CYTOCHROME C, the nuclear protein HISTONE H3, and 
SCD1 that is expressed in the endoplasmic reticulum, but not in the mitochondria. 
 
The subcellular localization of AGPAT4 was further investigated in HEK-293 cells 
transfected with pEGFP-N1 (control plasmid) or pEGFP-Agpat4. To coordinately 
visualize the endoplasmic reticulum or mitochondria, transfected cells were either stained 
with ER Tracker ™ Red dye, or co-transfected with the mitochondria localization plasmid 
pDsRed2-Mito, respectively. Imaging by confocal microscopy indicated that AGPAT4-
GFP in HEK-293 cells displayed a diffuse, punctate distribution (Fig. 6B) that was similar 
to immunodetectable AGPAT4 in primary neurons and glial cells (Fig. 5). Although 
AGPAT4-GFP predominately displayed an extra-nuclear localization, an increased 
intensity of green fluorescence was evident around the nucleus compared to the cytoplasm 
suggesting, in agreement with data from differential centrifugation (Fig. 6A), that a small 
fraction of AGPAT4 may localize, at least in part, to the nuclear membrane. Subcellular 
visualization of green fluorescent AGPAT4 based on coordinate imaging with either red 
fluorescent pDsRed2-Mito or ER Tracker ™ Red indicated that this enzyme 
predominately localizes to the mitochondria and not to the endoplasmic reticulum (Fig. 
7B). Analysis of the extent of co-localization using MIPAV (v7.0.1) software 
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demonstrates 86% co-localization between AGPAT4-GFP and pDsRed2-Mito, but only 
8% co-localization between AGPAT4-GFP and ER Tracker ™ Red. Transfection of cells 
with pEGFP-N1 alone led to a diffuse fluorescence throughout all areas of the cell. 
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AGPAT4 has acyl-CoA:lysophosphatidic acid acyltransferase (LPAAT) activity in vitro 
 
 
Figure 7: AGPAT4 is an acyl-CoA:lysophosphatidic acid acyltransferase in vitro. A, Immunoblot of Sf9 cells overexpressing 
AGPAT4. B, Protein lysates from Sf9 cells infected with either control or AGPAT4 baculovirus were assayed in vitro for acyl-CoA-
dependent lysophospholipid acyltransferase activity using [
14
C]oleoyl-CoA and a variety of lysophospholipid acyl acceptors. Bands 
corresponding to individual phospholipid species were quantified by liquid scintillation counting (n=3-4) (C). **P<0.01 vs. control.     
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To determine the activity of AGPAT4 in vitro, we produced cell lysates from Sf9 cells 
overexpressing AGPAT4 (Fig. 7A). Sequence analysis of AGPAT4 indicated the presence of 
conserved motifs that are common to the AGPAT family of enzymes (Table 2) leading us to 
initially investigate possible acyl-CoA-dependent lysophospholipid acyltransferase activities for 
this enzyme. We utilized [oleoyl-1-
14
C]-CoA as the acyl donor, and a variety of common 
lysophospholipids as acyl acceptors including LPA, LPC, LPE, and lysophosphatidylserine 
(LPS). However, our finding of a predominate mitochondrial localization (Fig. 6A,B) suggested 
the possibility that AGPAT4 may be involved in remodeling mitochondria-specific 
phospholipids, such as phosphatidylglycerol (PG) or CL. We therefore also screened a wider 
panel of potential lysophospholipid acceptors including less abundant or organelle-specific 
lysophospholipid species such as LPG, LPI, MLCL, and DLCL. Compared to reactions 
performed with control lysates, reactions with lysates overexpressing AGPAT4 produced 
significantly more radiolabeled PA from LPA as quantified by liquid scintillation counting (Fig. 
7B). Lysates overexpressing AGPAT4 increased esterification of [
14
C]oleoyl-CoA into LPA by 
~2.5-fold compared to control. Under our assay conditions, overexpression of AGPAT4 had no 
significant effect on incorporation of [
14
C]oleoyl-CoA into LPC, LPE, LPS, LPG, LPI, MLCL, 
or DLCL. This profile of in vitro lysophospholipid acyl-acceptor specificity is highly similar to 
that which has been previously reported (19,33). 
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Figure 8: pH dependency of AGPAT4 activity. Protein lysates from Sf9 cells infected with 
either control or AGPAT4 baculovirus were assayed in vitro for acyl-CoA-dependent 
lysophospholipid acyltransferase activity using [
14
C]oleoyl-CoA and lysophosphatidic acid at 
varying cellular pH. Bands corresponding to phosphatidic acid were quantified by liquid 
scintillation counting. Highest AGPAT4 activity was observed at pH 7.4 (n=3).  
Cellular pH varies significantly across different subregions of cells, and across organellar 
membranes. Optimal pH of AGPAT4 enzyme activity was assessed by in vitro assay of 
[
14
C]oleoyl-CoA:LPA acyltransferase activity in reaction buffer at varying pH levels, ranging 
from pH 7 to 8. We observed the highest AGPAT4 enzyme activity at pH 7.4 (Fig. 8). 
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AGPAT4 over expression increases the cellular content of PI 
 
 
 
Figure 9: AGPAT4 has acyl-CoA:lysophosphatidylinositol activity in vivo. Endogenous 
phospholipids from Sf9 cells overexpressing either AGPAT4 or control vector were analyzed for 
fatty acyl content of different phospholipid species. Samples were grown in triplicate in three 
separate experiments. * P<0.05 vs. control. 
Sf9 cells were infected with baculoviral AGPAT4 or control virus for 72 h, then 
harvested and extracted for total endogenous lipids. Individual phospholipids were resolved by 
TLC, identified by comparison with defined standards, scraped, and analyzed for fatty acyl 
composition and content, which was also used to calculate the corresponding cellular 
phospholipid levels. Cells overexpressing AGPAT4 had an ~72% greater total cellular PI content 
compared to control cells (37.14 ± 3.67 μg FA in PI/mg cells versus 21.62 ± 4.33 μg FA in 
PI/mg cells, respectively, P=0.0009)  (Fig. 9). There were no other significant differences in total 
levels of any of the other phospholipids analyzed, including PC, PE, PG, PS, or CL. 
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While total cellular PA content is important for mitochondrial metabolism and cell 
health, the specific fatty acyl composition of PA is also of critical importance (45,64). We 
therefore determined and quantified the fatty acyl composition of PA from Sf9 cells 
overexpressing AGPAT4 and found a significant increase in the total content of two saturated 
fatty acyl species (Figure 10). Among individual saturated fatty acyl species, we found a 
significantly higher content of lauric acid (C12:0) and arachidic acid (C20:0) in PA from cells 
overexpressing AGPAT4 as compared to controls. There were no significant differences in PA 
content of any of the monounsaturated fatty acid, or n-6 or n-3 PUFA species analyzed including 
docosahexanoic acid (22:6-3). Although DHA appeared to be marginally higher in the AGPAT4 
overexpressing group, this did not reach significance (P=0.17).  
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Figure 10: AGPAT4 overexpression results in higher levels saturated fatty acid species 
esterified in PA in vivo. Sf9 cells were grown in 250 mL flasks in triplicate, in three separate 
experiments, and infected with AGPAT4 or control baculovirus for 72 hours prior to harvest. 
Total lipids were extracted and resolved by TLC to isolate PA. Fatty acids in PA were identified 
and quantified by GC. Cells infected with AGPAT4 had in a higher level of lauric acid (171%) 
and arachidic acid (382%) esterified in PA as compared to controls. * P<0.05, ** P<0.01.  
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Figure 11: AGPAT4 overexpression does not result in higher levels of monounsaturated 
fatty acids esterified in PA in vivo. Sf9 cells were grown in 250 mL flasks plates in triplicate, in 
three separate experiments, and infected with AGPAT4 or control baculovirus for 72 hours prior 
to harvest. Total lipids were extracted and resolved by TLC to isolate PA. Fatty acids in PA were 
identified and quantified by GC. Cells infected with AGPAT4 did not result in a higher level of 
monounsaturated fatty acids esterified in PA as compared to controls.  
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Figure 12: AGPAT4 overexpression does not result in higher levels of n-6 polyunsaturated 
fatty acids esterified in PA in vivo. Sf9 cells were grown in 250 mL flasks plates in triplicate, in 
three separate experiments, and infected with AGPAT4 or control baculovirus for 72 hours prior 
to harvest. Total lipids were extracted and resolved by TLC to isolate PA. Fatty acids in PA were 
identified and quantified by GC. Cells infected with AGPAT4 did not result in a higher level of 
n-6 polyunsaturated fatty acids esterified in PA as compared to controls. 
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Figure 13: AGPAT4 overexpression does not result in higher levels of n-3 polyunsaturated 
fatty acids esterified in PA in vivo. Sf9 cells were grown in 250 mL flasks plates in triplicate, in 
three separate experiments, and infected with AGPAT4 or control baculovirus for 72 hours prior 
to harvest. Total lipids were extracted and resolved by TLC to isolate PA. Fatty acids in PA were 
identified and quantified by GC. Cells infected with AGPAT4 did not result in a higher level of 
n-3 polyunsaturated fatty acids esterified in PA as compared to controls.  
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AGPAT4 mRNA expression is developmentally and metabolically regulated  
 
 
Figure 14: AGPAT4 is regulated during murine embryogenesis. AGPAT4 mRNA expression 
in whole mouse embryos harvested at embryonic developmental day 10.5 (mid-2
nd
 trimester), 
14.5 (end of 2
nd
 trimester), and 18.5 (end of 3
rd
 trimester, immediately prior to birth) (n=4-6). 
Data are means ± S.E.M. 
a vs. b; b vs. c 
P<0.001, 
a vs. c
 P<0.05. 
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Figure 15: AGPAT4 is regulated during embryogenesis and in different metabolic states. 
AGPAT4 mRNA expression in various organs of mice that had access to food ad libitum (non-
fasted), or that underwent a 16 h overnight fast (fasted), or that were fasted and then re-fed for 4 
h prior to sacrifice (n=5-6) (B-F). Data are means ± S.E.M. 
a vs. b; b vs. c 
P<0.001; 
a vs. c, d; b vs. d
 
P<0.05. 
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Embryogenesis is a time of rapid cellular and organellar growth, with high demands for 
mitochondrial energy metabolism. It is also a time for organogenesis, with rapid development 
and expansion of specialized structures such as the central nervous system. To determine 
whether Agpat4 is regulated during embryogenesis, total RNA was isolated from mouse embryos 
on developmental days 10.5, 14.5, and 18.5, and analyzed by RT-qPCR for relative Agpat4 
expression normalized to 18s expression (Fig. 15). Agpat4 was upregulated 3.7-fold at 
developmental day 14.5 as compared to 10.5. Agpat4 mRNA levels then decreased to only 4% of 
developmental day 14.5 levels immediately prior to birth, on d18.5. 
 Genes involved in cellular energy metabolism must also respond to changes in the 
availability of nutrients in order to successfully transition between states of high and low energy 
availability. To determine whether Agpat4 expression is regulated in response to changing 
metabolic conditions, total RNA was prepared from multiple organs of mice provided with food 
ad libitum (i.e. in the non-fasted state), or subjected to a 16 h overnight fast (i.e. fasted), or with 
a 4 h period of re-feeding following t he overnight fast (i.e. refed). A pattern of fasting-induced 
expression of Agpat4 was evident in heart, kidney, and renal white adipose, with partial or 
complete suppression of Agpat4 induction occurring upon the reintroduction of nutrients (Figs. 
16B, C, D). The level of induction was sizable. Hearts from fasted mice showed an approximate 
12.5-fold increase in Agpat4 expression, kidneys showed an ~18.5-fold increase, and white-
adipose showed an ~4-fold increase in expression when compared to Agpat4 levels in the non-
fasted state. Upon re-feeding, kidney Agpat4 expression returned to non-fasted levels most 
rapidly, and was the only organ to exhibit a complete suppression of fasting-induced Agpat4 by 
4 h following the reintroduction of food. Despite the similarity in Apgat4 regulation between 
heart, kidney, and WAT, organ-specific differences were apparent. In particular, brain Agpat4 
 45 
expression was not significantly up- or down-regulated during the various metabolic states (Fig. 
16A). And, opposite to the pattern of regulation observed in heart, kidney, and WAT, livers from 
fasted mice showed a 6-fold down-regulation of Agpat4 as compared to the non-fasted state, 
which was followed by an approximate 12-fold induction of Agpat4 4 h after re-feeding (Fig. 
16E). These data indicate a complex pattern of Agpat4 regulation in response to changing 
developmental and metabolic conditions. 
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Chapter Six – Discussion 
In the current study, I report the characterization of acyl-CoA-dependent 
lysophosphatidic acid acyltransferase 4 (LPAAT4/AGPAT4) that functions in PA remodeling. 
To the best of our knowledge, this is the first study that identifies AGPAT4 localization to the 
mitochondria and function in PI synthesis. 
In agreement with the observations of others (19,25,33), we found that AGPAT4 is 
abundantly expressed in murine whole brain tissue. We extended these findings by investigating 
the expression of AGPAT4 in various subregions of the central nervous system including the 
olfactory bulbs, hippocampus, cerebellum, cortex, and brain stem, and found similar expression 
throughout. Furthermore, we detected AGPAT4 in both cultured primary cortical neurons and 
glial cells, indicating an important role for this enzyme throughout neural tissue. Examination of 
multiple other organs indicated largely ubiquitous expression of Agpat4, albeit at varying levels, 
in tissues as diverse as liver, kidney, lung, heart, renal white adipose tissue, and skeletal muscle. 
Although all studies to date (19,25,33) have reported the highest level of Agpat4 expression in 
brain, they also typically show Agpat4 expression in most tissues, albeit with some variation 
between reports, including ours. For example, while we, and others (25) found abundant Agpat4 
in adipose tissue, additional reports indicated detection of adipose Agpat4 mRNA at <10% of 
that found in brain (33). Similarly, while we found relatively abundant Agpat4 expression in 
heart, others report that this mRNA is barely detected in that organ (19,25,33). Abundance of 
Agpat4 mRNA in lung also ranges from barely detectable (21), to present at ~50% of the 
abundance in brain, or higher (19,25,33). 
Subcellular analysis of whole brain homogenates from wild type mice determined that 
AGPAT4 localizes predominately to the mitochondria, and also shows a small fraction in the 
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nuclear envelope. Although AGPAT5 has also been shown to localize to the mitochondria, the 
sub-mitochondrial fraction where this enzyme is resident has not yet been determined (11). A 
similar pattern of subcellular localization was evident for overexpressed AGPAT4. Our findings 
differ from one previous report. In that work, researchers found AGPAT4 localization to be 
highest in the ER, although subcellular fractionation was not employed (33). To the best of our 
knowledge, our findings make AGPAT4 only the second known AGPAT/LPAAT to 
preferentially localize to the mitochondria. Prior to this work, only AGPAT5 has been shown to 
have predominant mitochondrial localization (25), with most other AGPAT isoforms localizing 
preferentially to the endoplasmic reticulum (11). 
This initial discovery signified a likely role for AGPAT4 in mitochondrial lipid 
metabolism. Although the major cellular phospholipid species PC, PE, PS, PG, PI, PA, and CL 
can be detected in essentially all cellular organellar membranes to some extent, mitochondria 
show a highly characteristic pattern of PL species that is relatively well-conserved across 
mammals, yeast, and plants (39). The major species in the mammalian mitochondrial 
phospholipid bilayers are reported to be PC and PE, together forming over 2/3 of total 
phospholipid, and CL (15-20%) (3,39,40) and PI (~10%), with PS, PG, and PA together 
compromising only ~3% (39). In contrast, the phospholipid bilayers of mammalian plasma 
membranes have a much different composition, where the major species are PC (34%), PE 
(33%), and PS (10.5%), with PI and CL compromising only ~5% in total (41). The localization 
of AGPAT4 to the mitochondrial membrane suggested that this enzyme may have activity with 
other lysophospholipid species, including those that are enriched in this organelle. Analysis of 
the biochemical function of AGPAT4, however, demonstrated that the predominant in vitro 
enzymatic activity is the acyl-CoA-dependent synthesis of PA from LPA, precluding a direct 
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role for this enzyme in the synthesis of mitochondrial PG, CL, PI, PC, PE, or PS. AGPAT4 
showed a clear preference for activity at pH 7.4. This is in agreement with the finding of a 
predominate mitochondrial localization and it further suggests that AGPAT4 may function on 
the outer surface of the mitochondrion, where the cytoplasmic pH is ~7.4, rather than in the 
matrix where the pH is closer to 7.8. 
The role of AGPAT4 in PL synthesis in vivo was also investigated. PA is an important 
branching point in the Kennedy pathway. As end products, it can produce TAG, or feed into a 
wide variety of pathways to produce PLs including mitochondria-associated species. We focused 
our investigation on PL products of PA metabolism, rather than TAG, since the brain has 
extremely limited quantities of stored neutral lipid (42). To determine effects of increased PA 
synthesis on cellular phospholipid species, Sf9 cells overexpressing AGPAT4 were extracted and 
resolved to separate phospholipid from neutral lipid. Isolated PL were further resolved by TLC, 
scraped, and quantified by determination of associated fatty acids using GC. Surprisingly, 
however, only one major PL species was elevated – PI. A specific and highly statistically 
significant increase in PI content of Sf9 cells was observed with overexpression of AGPAT4. 
This effect could not be attributed to a non-specific change, such as an increase in mitochondrial 
content, since other mitochondria-specific PL species such as CL and PG were not elevated.  
The finding of a decrease in PI is of particular interest, considering that AGPAT4 is most 
highly expressed in the brain. PI is a relatively minor phospholipid in most tissues (41,43), but is 
enriched in the brain, particularly during aging (44). PI has many functions in different tissues, 
since it acts as a source for polyphosphorylated phosphoinositides that are released from 
membrane-bound PI by the action of phospholipase C to act in myriad signaling pathways. In 
brain, these signaling events include regulation of neurotransmission (45), and neuronal 
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exocytosis (46), with phosphoinositides implicated in regulating functional and structural 
plasticity (47-49). Loss of Agpat4 in the present study caused a greater than 50% reduction in 
brain levels of PI. This effect is substantial, far exceeding the slight (<10%) reduction observed 
in mice that have a deletion of Lpiat1, the enzyme that governs PI remodeling by acylating LPI 
(50). Agpat4 is therefore likely to play a role in the regulation of brain phosphoinositide-
mediated signaling and function. 
Overexpression of AGPAT4 in Sf9 cells resulted in the enrichment of endogenous 
cellular PA with total saturated fatty acids. In particular, significant increases in lauric (C12:0) 
and arachidic (C20:0) acid were evident. Interestingly, the content of docosahexanoic acid in PA 
was not enriched by overexpression of AGPAT4 in Sf9 cells, which is in contrast to a previous 
report by Eto et al, who found that AGPAT4 preferentially esterifies DHA at the sn-2 position of 
LPA. (33).  
 To provide preliminary investigation of a physiological function, we examined the 
regulation of Agpat4 gene expression with changing nutritional conditions, and during 
embryonic development. We found significant variation in the levels of Agpat4 in many tissues 
between the non-fasted, fasted, and refed states. Interestingly, this variation was not consistent 
among tissues, but rather showed a distinct pattern whereby hepatic Agpat4 mRNA expression 
was suppressed by fasting, but Agpat4 in extra-hepatic tissues, except for brain, was induced by 
fasting then partially or completely repressed to non-fasted levels by subsequent refeeding. Brain 
Agpat4 expression, uniquely, was refractive to changes in metabolic state. The reason for this 
differential expression is currently unknown, but the inverse regulation of this enzyme in 
different tissues, and lack of metabolic regulation in brain, suggest that complex transcriptional 
mechanisms are likely at work beyond the action of a single, major regulatory influence such as 
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insulin signaling. Of interest, our finding of significant tissue-specific differences in expression 
of Agpat4 with changing metabolic conditions may help to explain the variability in this measure 
between individual studies, since nutritional state was not standardized either across or within 
studies (19,25,33). In future, researchers should take care to control for this variable in 
experiments on gene expression. 
Elucidation of the factors governing transcriptional regulation of Agpat4 will also be 
important for understanding the role of this enzyme in embryonic development. Agpat4 
expression almost quadrupled between developmental days 10.5 and 14.5, and then fell to 15% 
of developmental day 10.5 levels immediately prior to birth. The reason for this change is 
currently unknown, and further studies will be required to determine whether this reflects 
specific changes occurring during these developmental timeframes, such as expansion of neural 
tissue, or widespread cellular expression during rapid organogenesis and development. 
Understanding cellular PI synthesis has important consequences for health and disease. 
Changes in mitochondrial phospholipid composition have been shown to alter mitochondrial 
respiration (51), and can induce cell apoptosis (52). Clinically, changes in mitochondrial 
phospholipid synthesis and membrane composition have been shown to cause disease, with 
changes in phosphoinositides playing a role in Lowe Syndrome (53), Dent disease (54), cancers 
(55-59), diabetes (60,61), and neurological defects such as Alzheimer’s disease and Down 
Syndrome (62-64). Future studies will focus on determining the role of altered AGPAT4-
mediated PI synthesis in mitochondrial metabolism and brain function. 
  
 51 
Chapter Seven – Study Limitations and Future Directions 
Limitations 
The major shortcoming in our identification and characterization of AGPAT4 is the use 
of baculoviral overexpression of this enzyme in the in vitro and in vivo characterization. There is 
no direct evidence that endogenous AGPAT4 functions in a similar manner to overexpressed 
enzyme. Immortal cell lines that show a high endogenous expression of AGPAT4 can be used to 
investigate the silencing of this gene by small interfering RNAs (siRNAs) to determine whether 
the loss of native AGPAT4 decreases PA remodeling and de novo PA synthesis. Gene ablation 
of Agpat4 in mice is another approach to investigate this question. Another limitation to this 
work is that crude protein lysates were used in characterizing this enzyme, and therefore may 
have contained other membrane-bound and non-membrane-bound proteins that could affect the 
assay, either indirectly by modifying activity of AGPAT4, or directly by functioning to produce 
additional AGPAT activity or affect PA synthesis or breakdown. The difficulty in purifying 
AGPAT for in vitro assay is a challenge faced by most acyltransferase researchers, given that the 
majority of these enzymes are integral membrane proteins. AGPAT4 is predicted to have 3-5 
transmembrane domains (Fig. 3), which renders it very difficult to remove from the membrane. 
Since our studies include recombinant AGPAT4 with 6x His tags, purifying this protein with a 
Ni-NTA purification system may yield purer protein that can be used in enzymological 
experiments, although the amount of protein generated may be severely limited. Future work 
will address these limitations, and extend studies reported in this thesis. 
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Future Directions 
  
 Phospholipids such as phosphatidylinositol are critical in cell signaling pathways needed 
to maintain a healthy state (46). In disease states, mitochondria can be oxidized by reactive 
oxygen species and undergo mitophagy, or mitochondrial-mediated apoptosis. Several 
mitochondrial-associated phospholipids including cardiolipin and phosphatidylinositol are potent 
regulators of these cellular processes (65-76). Mitochondrial-mediated apoptosis is a form of 
programmed cell death occurring due to factors released by damaged or dysfunctional 
mitochondria (75). It has been shown that phosphatidylinositol 3-phosphate is a key factor in 
mediating this process (65). Future work will be required to first confirm that AGPAT4 regulates 
PI synthesis in vivo, and then to determine the role of AGPAT4-mediated regulation of PI 
synthesis in brain mitochondrial functions including apoptosis, mitosis, and cellular energy 
metabolism. Species profiling of PI generated by AGPAT4 will be of particular interest, since PI 
in mammalian brain is generally esterified with stearic acid at the sn-1 position, and arachidonic 
acid at the sn-2 position (54-57), suggesting that the type and level of unsaturated fatty acids in 
PI may be important for cellular and mitochondrial functioning of this PL. Whether variation in 
the fatty acyl specificity of AGPAT4-derived PI occurs, and whether this alters the function of PI 
in cells, will be the focus of subsequent research.      
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Appendix 
Table 3: Fatty acyl species in PA from Sf9 cells overexpressing AGPAT4 or control vector. 
Fatty Acyl Species μmol fatty acid  S.E.M. / mg protein P-value 
 Control AGPAT4  
10:0 0.01  0.01 0.00  0.00 0.55 
12:0 0.07  0.03 0.19  0.01 0.0017 
14:0 0.55  0.24 0.61  0.14 0.69 
16:0 5.22  2.17 9.20  2.14 0.18 
18:0 7.32  2.66 13.14  3.54 0.18 
20:0 0.93  0.25 4.53  1.32 0.02 
22:0 0.69  0.25 1.48  0.39 0.10 
24:0 0.19  0.07 0.36  0.15 0.28 
∑SFA 15.00  5.14 29.55  6.89 0.09 
 
12:1 
 
0.01  0.01 
 
0.02  0.01 
 
0.25 
14:1 0.01  0.01 0.02  0.00 0.60 
16:1 0.84  0.18 1.17  0.27 0.29 
18:1n-7 0.25  0.06 0.22  0.04 0.77 
18:1n-9 1.33  0.22 1.74  0.32 0.27 
20:1n-9 0.03  0.01 0.04  0.01 0.62 
22:1n-9 0.35  0.15 0.53  0.20 0.44 
24:1n-9 0.05  0.02 0.06  0.03 0.72 
∑MUFA 2.87  0.50 3.79  0.55 0.20 
 
18:2n-6 
 
0.15  0.03 
 
0.17  0.07 
 
0.73 
18:3n-6 0.00  0.00 0.01  0.01 0.25 
20:2n-6 0.01  0.00 0.03  0.02 0.25 
20:3n-6 0.03  0.03 0.04  0.02 0.87 
20:4n-6 0.04  0.03 0.04  0.02 0.92 
22:2n-6 0.10  0.05 0.13  0.05 0.77 
22:4n-6 0.14  0.05 0.22  0.10 0.44 
22:5n-6 0.11  0.06 0.11  0.03 0.93 
∑n-6 PUFA 0.59  0.24 0.74  0.29 0.65 
 
18:3n-3 
 
0.01  0.00 
 
0.01  0.01 
 
0.60 
20:3n-3 0.32  0.13 0.49  0.19 0.46 
20:5n-3 0.03  0.02 0.05  0.02 0.43 
22:5n-3 0.02  0.01 0.02  0.01 0.96 
22:6n-3 0.03  0.02 0.06  0.02 0.17 
∑n-3 PUFA 0.41  0.18 0.64  0.24 0.41 
 
